1. IDF Diabetes Atlas. Sixth edition, 2014.
2. Thornalley PJ, Babaei-Jadidi R, Al AH et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50: 2164–70.
3. Manzetti S, Zhang J, van der Spoel D. Thiamin function, metabolism, uptake, and transport. Biochemistry 2014; 53 (5): 821–35.
4. Hellmann H, Mooney S. Review Vitamin B6: a molecule for human health? Molecules 2010; 15 (1): 442–59.
5. Ahn HJ, Min KW, Cho YO. Assessment of vitamin B(6) status in Korean patients with newly diagnosed type 2 diabetes. Nutr Res Pract 2011; 5 (1): 34–9.
6. O'Leary F, Samman S. Review Vitamin B12 in health and disease. Nutrients 2010; 2 (3): 299–316.
7. Al-Maskari MY, Waly MI, Ali A et al. Folate and vitamin B12 deficiency and hyperhomocysteinemia promote oxidative stress in adult type 2 diabetes. Nutrition 2012; 28 (7–8): e23–e26.
8. Ben Ahmed H, Bouzid K, Hassine M et al. Prevalence of non-conventional cardiovascular risk factors in Tunisian diabetics. Presse Med 2014;43 (1): e9–e16.
9. Molina M, Gonzalez R, Folgado J et al. Correlation between plasma concentrations of homocysteine and diabetic polyneuropathy evaluated with the Semmes-Weinstein monofilament test in patients with type 2 diabetes mellitus. Med Clin (Barc) 2013; 141 (9): 382–6.
10. Li J, Shi M, Zhang H et al. Relation of homocysteine to early nephropathy in patients with Type 2 diabetes. Clin Nephrol 2012; 77 (4): 305–10.
11. Jianbo L, Yuche C, Ming S et al. Association of homocysteine with peripheral neuropathy in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 93 (1): 38–42.
12. Ukinc K, Ersoz HO, Karahan C et al. Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009; 36 (2): 255–61.
13. Балаболкин М.И., Клебанова Е.М., Креминская В.М.. Лечение сахарного диабета и его осложнений. Руководство для врачей. М., Медицина, 2005; с. 432.
14. Day C. ADA-EASD diabetes guidance: individualised treatment of hyperglycaemia. Br J Diabet Vasc Dis 2012; 12: 146.
15. American Diabetes Association Position statement – Standards of Medical Care in Diabetes. Diabetes Care 2012; 35: S11–S63.
16. DeFronzo R, Goodman A. Efficacy of metformin in patients with noninsulin – dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541–9.
17. De-Jager J, Kooy A, Lehert P et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340: c2181.
18. Ting R, Szeto C, Chan M et al. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. Arch Intern Med 2006, 166: 1975–9.
19. Andre`s E, Noel E, Goichot B: Metformin-associated vitamin B12 deficiency. Arch Intern Med 2002, 162: 2251–2.
20. Токмакова А.Ю., Анциферов М.Б. Возможности использования нейромультивита в комплексной терапии полинейропатии у больных сахарным диабетом. Сахарный диабет. М.: Эндокринологический научный центр РАМН. 2001; 2 (7).
21. Удовиченко О.В. Эффективность Нейромультивита при диабетической полинейропатии. Новые лекарственные препараты. Вып. 2. 2001; с. 6–12.
22. Цагурия К.Г, Котешкова О.М. Савина Т.С. Нейромультивит в лечении диабетической периферической нейропатии. Новые лекарственные препараты. Вып. 2. 2001; с. 3–5.
Авторы
В.И.Новиков, К.Ю.Новиков
ГБОУ ВПО Смоленский государственный медицинский университет Минздрава России